TITLE

Phosphodiesterase 1 inhibition in the treatment of lower urinary tract dysfunction: From bench to bedside

AUTHOR(S)
Truss, Michael C.; Stief, Christian G.; Ückert, Stefan; Becker, Armin J.; Wefer, Jörg; Schultheiss, Dirk; Jonas, Udo
PUB. DATE
November 2001
SOURCE
World Journal of Urology;Nov2001, Vol. 19 Issue 5, p344
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Anticholinergic drugs are currently the therapy of choice to treat urgency and urge incontinence. However, muscarinergic receptor blockers with adequate selectivity for detrusor smooth muscle are not available. Also, in contrast to the normal detrusor, the unstable detrusor neurotransmission seems to be at least partially regulated by non-cholinergic (NANC) pathways. These factors may explain the common side effects and the limited clinical efficacy of these compounds. Specific modulation of intracellular second messenger pathways offers the possibility of organ selective manipulation of tissue function, specifically contraction and relaxation of smooth musculature. Because of their central role in the intracellular regulation of smooth muscle tone phosphodiesterases (PDEs) are an attractive pharmacological targets. The PDE 5 specific inhibitor sildenafil (Viagra) has revolutionized the treatment of patients with erectile dysfunction. Numerous other PDE inhibitors are currently under investigation for the treatment of various disorders. We investigated the role of PDEs in human detrusor smooth muscle. Our data demonstrate the presence of five PDE isoenzymes in human detrusor and suggest, for the first time, that the cAMP pathway and the calcium/calmodulin-stimulated PDE (PDE 1) are of functional importance in the intracellular regulation in this tissue in vitro. In addition, initial clinical data with the PDE 1 inhibitor vinpocetine in patients not responding to standard anticholinergic therapy indicate a possible role for vinpocetine in the treatment of urgency, urge incontinence and, possibly, low compliance bladder and interstitial cystitis. The results of a larger randomized, double-blind, placebo-controlled, multicenter trial with vinpocetine show a tendency in favor of vinpocetine over placebo; however, statistically significant results were documented for one parameter only. This might be due to the rather low dosage chosen and the small sample size. Further studies are necessary and currently underway to delineate the optimal dosage, indications and patient population. Modulation of intracellular key enzymes effecting second messenger metabolism, i.e. isoenzyme-selective PDE inhibition is a novel approach which possibly avoids the limitations of anticholinergic therapy in patients with lower urinary tract dysfunction.
ACCESSION #
15655947

 

Related Articles

  • Anticholinergic Therapy for Overactive Bladder Symptoms. Walling, Anne D. // American Family Physician;12/1/2003, Vol. 68 Issue 11, p2261 

    Presents an abstract of the study "Effectiveness of Anticholinergic Drugs Compared With Placebo in the Treatment of Overactive Bladder: Systemic Review," by P. Herbison et al., from the April 19, 2003 issue of the "British Medical Journal."

  • New Help for Urinary-Tract Pain. Krum, Angela J. // Parenting;Sep99, Vol. 13 Issue 7, p57 

    Presents information on interstitial cystitis, a nonchronic condition that mimics urinary tract infection in women. Treatment; Comments from C. Lowell Parsons, professor of urology at the University of California in San Diego. INSET: Drink Up!.

  • Review: Anticholinergic drugs improve motor function and disability in Parkinson disease.  // ACP Journal Club;Jan/Feb2004, Vol. 140 Issue 1, p15 

    This article focuses on a study regarding anticholinergics for symptomatic management of parkinson's disease (PD), published in the 2003 issue of the journal "Cochrane Database of Systematic Reviews." For this study the researchers selected studies if they were randomized controlled trials that...

  • Exploring New Findings in PBS/IC. Butrick, Charles W.; Teichman, Joel M. H. // Contemporary OB/GYN;Sep2007 Supplement, Vol. 52, p2 

    The article offers information on a continuing education program about painful bladder syndrome/interstitial cystitis (PBS/IC). The program is intended for urologists, obstetricians/gynecologists, and primary care physicians. PBS/IC is defined as a severely debilitating clinical condition of...

  • Interstitial Cystitis/Painful Bladder Syndrome. FRENCH, LINDA M.; BHAMBORE, NEELAM // American Family Physician;5/15/2011, Vol. 83 Issue 10, p1175 

    Interstitial cystitis/painful bladder syndrome affects more than 1 million persons in the United States, but the cause remains unknown. Most patients with interstitial cystitis/painful bladder syndrome are women with symptoms of suprapubic pelvic and/or genital area pain, dyspareunia, urinary...

  • The investigation and management of interstitial cystitis. Parsons, Matthew; Toozs-Hobson, Philip // Journal of the British Menopause Society;2005, Vol. 11 Issue 4, p132 

    Interstitial cystitis (IC) is a chronic inflammatory disorder of the bladder that is notoriously difficult to manage and can result in considerable morbidity. It very likely overlaps with painful bladder syndrome, but they are different conditions. The aetiology remains obscure, and the...

  • Updated AUA Guideline Helps Refine the Treatment Algorithm for Patients with IC/BPS. Lightner, Deborah J.; Hanno, Philip // AUANews;Oct2015, Vol. 20 Issue 10, p16 

    An interview with Philip Hanno, Panel Chair of the Interstitial Cystitis/Bladder Pain Sydrome (IC/BPS) Guideline, is presented. He discusses why the IC/BPS Guideline was revised in 2014. He says high-pressure, long duration hydrodistention or systemic (oral) long-term glucocorticoids should not...

  • WHEN SHOULD I SEE A UROLOGIST?  // AUANews;Winter2013 Urology Health Extra, p4 

    The article offers insights on when a person should see a urologist instead of a primary care doctor. It relates the case of a woman who was referred to a urologist and was later diagnosed with interstitial cystitis (IC) or painful bladder. Urologists specialize in treating conditions involving...

  • Stress may play 'critical role' in OAB, IC/PBS. Bronstein, Nancy // Urology Times;Jan2010, Vol. 38 Issue 1, p14 

    The article reports on a study which suggests the critical role of stress in the exacerbation and development of overactive bladder (OAB), interstitial cystitis/painful bladder syndrome. Investigators of the study characterized the changes in micturation frequency, anxiety, bladder pathology and...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics